{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:47:47Z","timestamp":1793119667638,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA279749-01A1"],"award-info":[{"award-number":["1R01CA279749-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ygyno.2024.12.019","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T17:51:51Z","timestamp":1736358711000},"page":"73-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer"],"prefix":"10.1016","volume":"193","author":[{"given":"Jibran","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettzy","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad R.","family":"Khawaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israa","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizve","family":"Barrientos-Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriela","family":"Raso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaan S.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela T.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2024.12.019_bb0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"10333","key":"10.1016\/j.ygyno.2024.12.019_bb0010","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ygyno.2024.12.019_bb0015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1158\/2159-8290.CD-11-0039","article-title":"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability","volume":"1","author":"Cheung","year":"2011","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.ygyno.2024.12.019_bb0020","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1158\/0008-5472.CAN-3487-2","article-title":"K-Ras and H-Ras activation promote distinct consequences on endometrial cell survival","volume":"64","author":"Ninomiya","year":"2004","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.ygyno.2024.12.019_bb0025","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1517\/14728222.12.9.1139","article-title":"Akt as a therapeutic target in cancer","volume":"12","author":"Steelman","year":"2008","journal-title":"Expert Opin. Ther. Tar."},{"issue":"21","key":"10.1016\/j.ygyno.2024.12.019_bb0030","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","article-title":"The PI3K\/AKT\/mTOR Pathway as a Therapeutic Target in Endometrial Cancer","volume":"18","author":"Slomovitz","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ygyno.2024.12.019_bb0035","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/modpathol.2011.208","article-title":"Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing","volume":"25","author":"Djordjeyic","year":"2012","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2024.12.019_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/0471142905.hg1011s57","article-title":"The catalogue of somatic mutations in cancer (COSMIC)","author":"Forbes","year":"2008","journal-title":"Curr. Protoc. Hum. Genet."},{"issue":"5","key":"10.1016\/j.ygyno.2024.12.019_bb0045","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.12.019_bb0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/IGC.0b013e318207dac7","article-title":"Metformin Reverses Progestin Resistance in Endometrial Cancer Cells by Downregulating GloI Expression","volume":"21","author":"Zhang","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2024.12.019_bb0055","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2337\/dc08-2175","article-title":"New users of metformin are at low risk of incident cancer a cohort study among people with type 2 diabetes","volume":"32","author":"Libby","year":"2009","journal-title":"Diabetes Care"},{"issue":"20","key":"10.1016\/j.ygyno.2024.12.019_bb0060","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1200\/JCO.2009.19.6410","article-title":"Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer","volume":"27","author":"Jiralerspong","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2024.12.019_bb0065","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1447-0756.2011.01839.x","article-title":"Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression","volume":"38","author":"Dong","year":"2012","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"1","key":"10.1016\/j.ygyno.2024.12.019_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2013.03.008","article-title":"Chemopreventive effects of metformin on obesity-associated endometrial proliferation","volume":"209","author":"Zhang","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.12.019_bb0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ygyno.2009.09.024","article-title":"Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy","volume":"116","author":"Cantrell","year":"2010","journal-title":"Gynecol Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.12.019_bb0080","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ygyno.2012.01.009","article-title":"Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway","volume":"125","author":"Hanna","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"3\u20135","key":"10.1016\/j.ygyno.2024.12.019_bb0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jsbmb.2010.12.006","article-title":"Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells","volume":"126","author":"Xie","year":"2011","journal-title":"J.Steroid Biochem."},{"issue":"5","key":"10.1016\/j.ygyno.2024.12.019_bb0090","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1940-6207.CAPR-08-0081","article-title":"The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase","volume":"1","author":"Zakikhani","year":"2008","journal-title":"Cancer Prev. Res."},{"issue":"22","key":"10.1016\/j.ygyno.2024.12.019_bb0095","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin\u2013dependent translation initiation in breast cancer cells","volume":"67","author":"Dowling","year":"2007","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ygyno.2024.12.019_bb0100","doi-asserted-by":"crossref","first-page":"909","DOI":"10.4161\/cc.8.6.7933","article-title":"Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro","volume":"8","author":"Alimova","year":"2009","journal-title":"Cell Cycle"},{"issue":"14","key":"10.1016\/j.ygyno.2024.12.019_bb0105","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.1158\/0008-5472.CAN-06-4447","article-title":"Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth","volume":"67","author":"Buzzai","year":"2007","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ygyno.2024.12.019_bb0110","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.celrep.2015.07.016","article-title":"A positive feedback loop between Akt and mTORC2 via SIN1 phosphorylation","volume":"12","author":"Yang","year":"2015","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.ygyno.2024.12.019_bb0115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10549-010-0763-9","article-title":"Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells","volume":"123","author":"Zakikhani","year":"2010","journal-title":"Breast Cancer Res. Tr."},{"issue":"13","key":"10.1016\/j.ygyno.2024.12.019_bb0120","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1158\/0008-5472.CAN-10-1769","article-title":"Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1","volume":"71","author":"Ben Sahra","year":"2011","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ygyno.2024.12.019_bb0125","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1517\/13543784.2013.795947","article-title":"Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials","volume":"22","author":"Naing","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"12","key":"10.1016\/j.ygyno.2024.12.019_bb0130","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1517\/13543784.2013.833604","article-title":"Metformin: an old drug with new potential","volume":"22","author":"Hajjar","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"20","key":"10.1016\/j.ygyno.2024.12.019_bb0135","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.22.1630","article-title":"Metformin in Breast Cancer: Time for Action","volume":"27","author":"Goodwin","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2024.12.019_bb0140","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.2337\/db14-1132","article-title":"Metformin and rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct microRNA-regulated mechanisms","volume":"64","author":"Cifarelli","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.ygyno.2024.12.019_bb0145","doi-asserted-by":"crossref","unstructured":"Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, et al. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced\/refractory cancers. Cancer Chemother. Pharmacol. 2016;77(5):973\u20137, https:\/\/doi.org\/10.1007\/s00280-016-3009-7.","DOI":"10.1007\/s00280-016-3009-7"},{"issue":"2","key":"10.1016\/j.ygyno.2024.12.019_bb0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2024.12.019_bb0155","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.12.019_bb0160","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"03","key":"10.1016\/j.ygyno.2024.12.019_bb0165","article-title":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)","volume":"4","author":"U.S. Department of Health and Human Services","year":"2010","journal-title":"Version"},{"issue":"1","key":"10.1016\/j.ygyno.2024.12.019_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control. Clin. Trials"},{"issue":"23","key":"10.1016\/j.ygyno.2024.12.019_bb0175","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"7447","key":"10.1016\/j.ygyno.2024.12.019_bb0180","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"22 Shen Hui 22 JHBSBBMSLPHTJTJVDBDJWDJ, 23 IfSBRSMSI. Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ygyno.2024.12.019_bb0185","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1158\/1078-0432.CCR-10-0540","article-title":"A unique spectrum of somatic PIK3CA (p110\u03b1) mutations within primary endometrial carcinomas","volume":"17","author":"Rudd","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.ygyno.2024.12.019_bb0190","doi-asserted-by":"crossref","first-page":"13012","DOI":"10.1073\/pnas.1918845117","article-title":"Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1","volume":"117","author":"Xie","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.ygyno.2024.12.019_bb0195","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/bjc.2012.477","article-title":"KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer","volume":"107","author":"Birkeland","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"24","key":"10.1016\/j.ygyno.2024.12.019_bb0200","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group","volume":"29","author":"Oza","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.12.019_bb0205","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/cncr.28414","article-title":"Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer","volume":"120","author":"Mackay","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2024.12.019_bb0210","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.12.019_bb0215","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1078-0432.CCR-19-0471","article-title":"Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II StudyEverolimus, Letrozole, and Metformin","volume":"26","author":"Soliman","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.12.019_bb0220","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ygyno.2020.06.013","article-title":"A randomized phase II\/III study of paclitaxel\/carboplatin\/metformin versus paclitaxel\/carboplatin\/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: an NRG Oncology\/GOG study","volume":"159","author":"Bae-Jump","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.12.019_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.12.019_bb0230","series-title":"Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601)","author":"Antill","year":"2019"},{"issue":"30","key":"10.1016\/j.ygyno.2024.12.019_bb0235","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.19.01021","article-title":"Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent\/persistent endometrial cancer","volume":"37","author":"Konstantinopoulos","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582401237X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582401237X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:58:23Z","timestamp":1773835103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582401237X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":47,"alternative-id":["S009082582401237X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.12.019","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}